Clinical Trial Update: A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial investigating Certolizumab Pegol in children and adolescents with Crohn's disease was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Certolizumab pegol (certolizumab pegol)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Crohn's Disease | Phase 3 | Status: WITHDRAWN